Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa : a cohort study

Show simple item record

dc.contributor.author Fielding, Katherine L.
dc.contributor.author Charalambous, Salome
dc.contributor.author Stenson, Amy L.
dc.contributor.author Pemba, Lindiwe F.
dc.contributor.author Martin, Desmond J.
dc.contributor.author Wood, Robin
dc.contributor.author Churchyard, Gavin J.
dc.contributor.author Grant, Alison D.
dc.date.accessioned 2008-09-09T05:52:27Z
dc.date.available 2008-09-09T05:52:27Z
dc.date.issued 2008-07
dc.description.abstract BACKGROUND: Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined. METHODS: Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400 copies/ml. RESULTS: Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953 (81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 106/l). 71% (681/ 953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001– 100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92– 6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage 1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported 100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log decrease in viral load. CONCLUSION: Virological response at six weeks after ART start was the strongest predictor of suboptimal virological outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks. Site of delivery had an important influence on virological outcomes; factors at the health system level which influence outcome need further investigation to guide development of effective ART programmes. en
dc.description.sponsorship This study was funded by Anglo American plc. KLF was supported by the Aurum Institute for Health Research and a Bill and Melinda Gates Foundation grant for the Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE) Biostatistics core, SC, LFP, GJC by Aurum Institute for Health Research, ALS from the Trustees of LSHTM and Aurum Institute for Health Research, and ADG by a UK Department of Health Public Health Career scientist award en
dc.format.extent 270301 bytes
dc.format.mimetype application/pdf
dc.identifier.citation Fielding, KL, Charalambous, S, Stenson, AL, Pemba, LF,Martin, DJ, Wood, R, Churchyard, GJ, & Grant, AD 2008, 'Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study', BMC Infectious Diseases, vol. 8, no. 93. [http://www.biomedcentral.com/bmcinfectdis/] en
dc.identifier.issn 1471-2334
dc.identifier.other 10.1186/1471-2334-8-93
dc.identifier.uri http://hdl.handle.net/2263/6978
dc.language.iso en en
dc.publisher BioMed Central en
dc.rights BioMed Central en
dc.subject Antiretroviral en
dc.subject Virology en
dc.subject.lcsh Virology
dc.subject.lcsh Antiretroviral agents -- South Africa
dc.subject.mesh
dc.title Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa : a cohort study en
dc.type Article en


Files in this item

This item appears in the following Collection(s)

Show simple item record